Registry of Local Recurrences After Breast-conserving Surgery

NCT ID: NCT05406661

Last Updated: 2023-10-19

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Total Enrollment

3000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-12-01

Study Completion Date

2026-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The ReLoCC project is a prospective, multicenter, clinical study to register cases of local recurrence after breast-conserving surgery, in centers dedicated to the treatment of breast cancer, in Portugal and Spain.

The comparison of the results obtained will allow the optimization of the treatment, making it increasingly personalized.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Breast Cancer Recurrent

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Female patients
2. Age \> 18 years
3. Patients who have previously undergone breast-conserving surgery as part of the treatment of invasive or non-invasive (in situ) breast cancer

1. and adjuvant breast RT: total (WBI) or partial (PBI)
2. without adjuvant radiotherapy to the breast
4. Recent histological diagnosis of homolateral, invasive or non-invasive (in situ) breast carcinoma

Exclusion Criteria

1. Male
2. Age \< 18 years
3. Stage 4 at diagnosis
4. Patients operated outside the participating Centers and for whom it is not possible to obtain complete information regarding the primary treatment
5. History of other primary invasive malignant tumor (except non-melanoma skin carcinomas)
6. Patients already treated for another local recurrence of breast carcinoma
7. Absence of clinical follow-up and records in clinical process
Minimum Eligible Age

18 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Centro Hospitalar Universitário São João, EPE

UNKNOWN

Sponsor Role collaborator

Universidade do Porto

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

José Luis Fougo, MD, PhD

Role: STUDY_DIRECTOR

Centro de Mama - Centro Hospitalar Universitário de São João

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Diana Gonçalves, MD, PhDc

Role: CONTACT

(+351) 913017481

Janete Santos, PhD

Role: CONTACT

(+351) 225 513 600

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

R_ReLoCC

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.